|
ES2828739T3
(es)
|
2006-04-07 |
2021-05-27 |
Aerpio Pharmaceuticals Inc |
Anticuerpos que se unen a la proteína tirosina fosfatasa beta humana (HPTP-beta) y sus usos
|
|
MX363351B
(es)
|
2011-10-13 |
2019-03-20 |
Aerpio Therapeutics Inc |
Un agente de unión a hptp?-ecd para usarse en el tratamiento de síndrome de fuga vascular.
|
|
WO2015200905A2
(en)
|
2014-06-28 |
2015-12-30 |
Oligasis, Llc |
Dual pdgf/vegf antagonists
|
|
AU2016286108B2
(en)
|
2015-06-30 |
2021-03-11 |
Pfizer Inc. |
BTLA fusion protein agonists and uses thereof
|
|
IL290457B2
(en)
|
2015-12-30 |
2025-02-01 |
Kodiak Sciences Inc |
Antibodies and their conjugates
|
|
BR112019000071A2
(pt)
|
2016-07-07 |
2019-07-02 |
Bolt Biotherapeutics Inc |
conjugados adjuvantes de anticorpo
|
|
WO2018222718A1
(en)
|
2017-05-30 |
2018-12-06 |
Bristol-Myers Squibb Company |
Treatment of lag-3 positive tumors
|
|
JP7301002B2
(ja)
|
2017-05-30 |
2023-06-30 |
ブリストル－マイヤーズ スクイブ カンパニー |
抗ｌａｇ－３抗体または抗ｌａｇ－３抗体および抗ｐｄ－１もしくは抗ｐｄ－ｌ１抗体を含む組成物
|
|
CA3092588A1
(en)
|
2018-03-02 |
2019-09-06 |
Kodiak Sciences Inc. |
Il-6 antibodies and fusion constructs and conjugates thereof
|
|
EP3856245A4
(en)
|
2018-09-24 |
2022-10-26 |
EyePoint Pharmaceuticals, Inc. |
MULTISPECIFIC ANTIBODIES AGAINST HPTP - BETA (VE-PTP) AND VEGF
|
|
CN113518823B
(zh)
*
|
2019-01-07 |
2025-05-02 |
托马斯杰斐逊大学 |
多功能的融合蛋白及其用途
|
|
EP3937984A1
(en)
|
2019-03-15 |
2022-01-19 |
Bolt Biotherapeutics, Inc. |
Immunoconjugates targeting her2
|
|
EP3972690A4
(en)
*
|
2019-05-23 |
2023-07-05 |
Janssen Biotech, Inc. |
METHOD OF TREATMENT OF INFLAMMATORY BOWEL DISEASE USING COMBINATION THERAPY OF ANTIBODIES TO IL-23 AND TNF-ALPHA
|
|
KR102815892B1
(ko)
*
|
2019-06-10 |
2025-06-04 |
샨동 보안 바이오테크놀로지 컴퍼니, 리미티드 |
PDL1 및 TGFβ에 대한 2기능성 융합 단백질 및 이의 용도
|
|
WO2020252421A2
(en)
*
|
2019-06-14 |
2020-12-17 |
Cugene, Inc. |
Novel interleukin-2 variants and bifunctional fusion molecules thereof
|
|
US20220235131A1
(en)
*
|
2019-06-17 |
2022-07-28 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods of treating infections by blocking pathogen mimics of cd47
|
|
WO2021007428A2
(en)
*
|
2019-07-09 |
2021-01-14 |
The Johns Hopkins University |
Molecules, compositions and methods for treatment of cancer
|
|
CN110627905B
(zh)
*
|
2019-09-18 |
2021-04-27 |
中国医学科学院肿瘤医院 |
靶向vegf与egfr的双功能融合蛋白及其应用
|
|
WO2021055994A1
(en)
*
|
2019-09-22 |
2021-03-25 |
Bristol-Myers Squibb Company |
Quantitative spatial profiling for lag-3 antagonist therapy
|
|
CN112574314A
(zh)
*
|
2019-09-30 |
2021-03-30 |
和铂医药(苏州)有限公司 |
一种融合蛋白及其应用
|
|
CA3157509A1
(en)
|
2019-10-10 |
2021-04-15 |
Kodiak Sciences Inc. |
Methods of treating an eye disorder
|
|
EP4054723A1
(en)
*
|
2019-11-08 |
2022-09-14 |
Bristol-Myers Squibb Company |
Lag-3 antagonist therapy for melanoma
|
|
CA3158047A1
(en)
*
|
2019-12-11 |
2021-06-17 |
Yunying CHEN |
Bi-functional antibody against pd-l1 and tgf?
|
|
WO2021123432A1
(en)
*
|
2019-12-20 |
2021-06-24 |
Ares Trading S.A. |
Igg:tgfbetarii fusion protein composition
|
|
US11045546B1
(en)
|
2020-03-30 |
2021-06-29 |
Cytodyn Inc. |
Methods of treating coronavirus infection
|
|
KR20230003178A
(ko)
*
|
2020-04-29 |
2023-01-05 |
치아타이 티안큉 파마수티컬 그룹 주식회사 |
PD-1 및 TGF-β에 대한 이중 기능성 단백질
|
|
CA3181949A1
(en)
*
|
2020-05-05 |
2021-11-11 |
Janssen Biotech, Inc. |
Methods of treating crohn's disease with anti-il23 specific antibody
|
|
KR20230010251A
(ko)
|
2020-05-13 |
2023-01-18 |
보넘 테라퓨틱스, 인크. |
단백질 복합체의 조성물 및 그의 사용 방법
|
|
CA3183927A1
(en)
|
2020-05-21 |
2021-11-25 |
Janssen Biotech, Inc. |
Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
|
|
CA3183673A1
(en)
*
|
2020-06-26 |
2021-12-30 |
Robert Allen |
Oncolytic herpes simplex viruses (hsv) expressing immunomodulatory fusion proteins
|
|
AU2021308574A1
(en)
*
|
2020-07-13 |
2023-03-09 |
Janssen Biotech, Inc. |
Safe and effective method of treating psoriatic arthritis with anti-IL23 specific antibody
|
|
WO2022037606A1
(en)
*
|
2020-08-19 |
2022-02-24 |
Bio-Thera Solutions, Ltd. |
Liquid formulations comprising high concentrations humanized antibodies for treating il-6 related diseases
|
|
CA3196496A1
(en)
|
2020-10-23 |
2022-04-28 |
Laurence David TOMS |
Lag-3 antagonist therapy for lung cancer
|
|
CN114539415B
(zh)
*
|
2020-11-24 |
2024-02-02 |
普米斯生物技术(珠海)有限公司 |
一种抗PD-L1/VEGF/TGF-β多特异性抗体及其用途
|
|
EP4251650A4
(en)
*
|
2020-11-27 |
2024-10-23 |
Elpiscience (Suzhou) Biopharma, Ltd. |
Novel conjugate molecules targeting cd39 and tgfbeta
|
|
CN116897165A
(zh)
*
|
2021-02-27 |
2023-10-17 |
典晶生物医药科技(苏州)有限公司 |
靶向il-6受体和血管生成因子的抗体融合蛋白
|
|
EP4305062A1
(en)
*
|
2021-03-12 |
2024-01-17 |
Janssen Biotech, Inc. |
Method of treating psoriatic arthritis patients with inadequate response to tnf therapy with anti-il23 specific antibody
|
|
BR112023018353A2
(pt)
*
|
2021-03-12 |
2024-02-06 |
Janssen Biotech Inc |
Método seguro e eficaz para tratamento da artrite psoriática com anticorpo específico anti-il23
|
|
CN113698493B
(zh)
*
|
2021-08-09 |
2022-05-31 |
北京东方百泰生物科技股份有限公司 |
一种针对VEGF和TGF-β的双功能蛋白及其应用
|
|
JP7767613B2
(ja)
|
2021-11-15 |
2025-11-11 |
システィミューン，インコーポレイテッド |
二重特異性抗体－カンプトテシン薬物複合体及びその製薬的使用
|
|
WO2023146654A1
(en)
*
|
2022-01-31 |
2023-08-03 |
Fbd Biologics Limited |
Engineered pd-1 variants and methods of use thereof
|
|
EP4249510A1
(en)
*
|
2022-03-22 |
2023-09-27 |
Stealth IO |
Novel formats of anti-cd28/spd-1 fusion constructs
|
|
CN117624375A
(zh)
*
|
2022-08-30 |
2024-03-01 |
北京卡替医疗技术有限公司 |
增强受体、表达增强受体的免疫细胞及其用途
|
|
CN116554300B
(zh)
*
|
2023-04-27 |
2023-10-24 |
湖北医药学院 |
一种能与艰难拟梭菌毒素TcdB相互作用的多肽及其应用
|
|
WO2026085300A1
(en)
*
|
2024-10-16 |
2026-04-23 |
Flagship Pioneering Innovations Vii, Llc |
Compositions and methods
|
|
CN122167587A
(zh)
*
|
2024-12-04 |
2026-06-09 |
科辉智药(深圳)新药研究中心有限公司 |
一种抗pd-l1和hhla2双特异性抗体及其制备方法和应用
|